Words

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

Home > Words

At Woodford we have set new standards for communicating with our clients since our establishment in 2014. We never forget whose money we are investing and we believe that investors have a right to understand how their investments are being managed – and also have a choice in how they are communicated with.

Here, you can find out what we’re thinking as we think it and let us have your immediate comments and questions on individual pieces or more generally on our communication programme. Articles are written primarily by our team, with additional contributions from respected industry figures, and feature a mix of articles, thoughts, observations and commentary relating to events and trends in the global financial markets.

We’re keen to ensure our content is of interest and value to our existing and prospective clients so please do get in touch and let us know what you think.

Blog

Budget 2017: ‘shrewd and appropriate’

Neil Woodford 22 November 2017 4 min read

Having listened into today’s Budget from Chancellor Hammond, I thought I would share some quick initial thoughts with you…

Read more

Blog

An update on Prothena

Neil Woodford 22 November 2017 7 min read

There is demand for an update on our view of Prothena, following recent coverage and last week’s R&D day. This isn’t a response to any particular note. Research is published on a range of stocks every day, covering a range of different views – we haven’t commented on them in the past, nor do we intend to start now. It is simply an update on where we are today, with a focus on the opportunity on NEOD001 in the rare disease, AL Amyloidosis.

Read more

Insights

Income Focus Fund update, October 2017

Mitchell Fraser-Jones 17 November 2017 6 min read

The portfolio delivered a positive return in October with the latest quarterly income distribution indicating that the fund is on track to deliver its income objective of 5p in its first full calendar year…

Read more

Insights

Patient Capital Trust update, October 2017

Mitchell Fraser-Jones 17 November 2017 4 min read

In October, we continued to see meaningful operational progress across a number of holdings, with encouraging news coming from the likes of Idex, ReNeuron and Mereo BioPharma…

Read more

Insights

Equity Income Fund update, October 2017

Mitchell Fraser-Jones 17 November 2017 5 min read

Global markets continued to rise in October, with relatively upbeat economic data allowing investors to shrug off political concerns in Europe and Asia. Against this backdrop, the fund delivered a modestly positive return during the month…

Read more

Blog

Brexit – where are we now?

Mitchell Fraser-Jones 8 November 2017 6 min read

Leaving the politics to one side, we have commissioned Capital Economics to look purely at the economic consequences of Brexit. We’ve found this exclusive report very valuable, interesting and ultimately, from the perspective of our investment strategy, very reassuring. It reinforces our confidence that the portfolios are positioned very appropriately for the long-term and that is why we want to share it with you…

Read more

Insights

Income Focus Fund update, September 2017

Mitchell Fraser-Jones 19 October 2017 4 min read

The UK stock market declined slightly in September, despite continued positive momentum in most other major equity markets. Sterling was strong, as the Bank of England indicated that interest rates may rise in November. We do not believe that this heralds the start of significantly tighter monetary policy, but it is a sign that the UK economy is in much better shape than many commentators have suggested…

Read more

Insights

Patient Capital Trust update, September 2017

Mitchell Fraser-Jones 19 October 2017 6 min read

September was quite a busy month of operational news for companies in the Woodford Patient Capital Trust portfolio, with updates from the likes of Federated Wireless, Immunocore, and Prothena…

Read more

Insights

Equity Income Fund roundup, September 2017

Mitchell Fraser-Jones 19 October 2017 4 min read

The UK stock market declined slightly in September, despite continued positive momentum in most other major equity markets. Currency movements explain much of this disparity, with a recovery in the US dollar against most other currencies, undermining some of the consensual market views that have worked well for much of this year…

Read more

Blog

Increasing UK focus

Mitchell Fraser-Jones 10 October 2017 7 min read

In light of the recent changes to the portfolio strategy, we thought it would be interesting to take a look at how the Woodford funds’ geographical exposure has evolved.

Read more

What are the risks?

  • The value of investments and any income from them may go down as well as up, so you may get back less than you invested
  • Past performance cannot be relied upon as a guide to future performance
  • The annual management charge applicable to the funds is charged to capital, so the income of the funds may be higher but capital growth may be restricted or capital may be eroded
  • The funds may invest in other transferable securities, money market instruments, warrants, collective investment schemes and deposits
  • The funds may invest in overseas securities and be exposed to currencies other than pound sterling.
  • The CF Woodford Income Focus Fund will be invested in a concentrated portfolio of securities – the fund is not restricted by reference to any geographical region, sector or market capitalisation
  • The CF Woodford Equity Income Fund may invest in unquoted securities, which may be less liquid and more difficult to realise than publicly traded securities

Important information

Before investing, you should read the Key Investor Information Document (KIID) for the fund, and the Prospectus which, along with our terms and conditions, can be obtained from the downloads page or from our registered office. If you have a financial adviser, you should seek their advice before investing. Woodford Investment Management Ltd is not authorised to provide investment advice.

You should note that capital is at risk with these investments and you may get back less than you invested. The value of the fund or trust as well as any income paid will fluctuate which may partly be the result of exchange rate changes.

The price of shares in the Woodford Patient Capital Trust is determined by market supply and demand, and this may be different to the net asset value of the trust.

The Woodford Patient Capital Trust currently intends to conduct its affairs so that its securities can be recommended by IFAs to ordinary retail investors in accordance with the FCA’s rules in relation to non-mainstream investment products and intends to continue to do so for the foreseeable future. The securities are excluded from the FCA’s restrictions which apply to non-mainstream investment products because they are shares in an investment trust.

Young businesses have a different risk profile to mature blue-chip companies – risks are much more stock-specific, which implies a lower correlation with equity markets and the wider economy. Long-term outcomes are more binary – extremely attractive rewards for success but some businesses will inevitably fail to fulfil their potential and this may expose Woodford Patient Capital Trust investors to the risk of capital losses. As it can take years for young businesses to fulfil their potential, this investment requires patience.

Woodford Investment Management Ltd is authorised and regulated by the Financial Conduct Authority (firm reference number 745433). Incorporated in England and Wales, company number 10118169. Registered address 9400 Garsington Road, Oxford OX4 2HN.

Woodford Patient Capital Trust plc is incorporated in England and Wales, company number 09405653. Registered as an investment company under section 833 of the Companies Act 2006. Registered address Beaufort House, 51 New North Road, Exeter, EX4 4EP.

The Woodford Funds (Ireland) ICAV (the “Fund”) has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: info@oligofunds.ch. The Fund’s Swiss paying agent is Neue Helvetische Bank AG. All fund documentation including, Prospectus, Key Investor Information Documents, Instrument of Incorporation and financial reports may be obtained free of charge from the Swiss Representative in Lausanne. The place of performance and jurisdiction for all shares distributed in or from Switzerland is at the registered office of the Swiss Representative. Fund prices can be found at www.fundinfo.com.

© 2017 Woodford Investment Management Ltd.
All rights reserved.

By using this website you are automatically agreeing to the Woodford Investment Management Ltd privacy statement